Cargando…

Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells

Cisplatin is a potent chemotherapeutic drug for ovarian cancer (OC) treatment. However, its efficacy is significantly limited due to the development of cisplatin resistance. Although the acquisition of cisplatin resistance is a complex process involving various molecular alterations within cancer ce...

Descripción completa

Detalles Bibliográficos
Autor principal:	Chun, Jaemoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419319/ https://www.ncbi.nlm.nih.gov/pubmed/37569773 http://dx.doi.org/10.3390/ijms241512397

Ejemplares similares

Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation
por: Zhao, Lili, et al.
Publicado: (2019)

Isoalantolactone Increases the Sensitivity of Prostate Cancer Cells to Cisplatin Treatment by Inducing Oxidative Stress
por: Huang, Hang, et al.
Publicado: (2021)

MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway
por: Lin, Zhilai, et al.
Publicado: (2020)

Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells
por: Sima, Ni, et al.
Publicado: (2018)

Cordycepin Resensitizes T24R2 Cisplatin-Resistant Human Bladder Cancer Cells to Cisplatin by Inactivating Ets-1 Dependent MDR1 Transcription
por: Oh, Sang-Seok, et al.
Publicado: (2020)

Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2
por: Ke, Bin, et al.
Publicado: (2019)

Osthole resensitizes CD133(+) hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway
por: Ye, Junfeng, et al.
Publicado: (2020)

Hyperthermic intrathoracic chemotherapy with cisplatin for ovarian cancer with pleural metastasis
por: Jun, Su Youn, et al.
Publicado: (2017)

Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
por: Kim, Myung Joo, et al.
Publicado: (2012)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin
por: Takahashi, Ryosuke, et al.
Publicado: (2023)

Isoalantolactone suppresses gallbladder cancer progression via inhibiting the ERK signalling pathway
por: Lv, Xingyu, et al.
Publicado: (2023)

Cisplatin-Based Chemotherapy of Human Cancers
por: Brown, Andrea, et al.
Publicado: (2019)

Targeting Apoptosis Pathways in Cancer with Alantolactone and Isoalantolactone
por: Rasul, Azhar, et al.
Publicado: (2013)

Potentiation of Cisplatin Cytotoxicity in Resistant Ovarian Cancer SKOV3/Cisplatin Cells by Quercetin Pre-Treatment
por: Hasan, Aseel Ali, et al.
Publicado: (2023)

Apoptosis Induction with Combined Use of Cisplatin and Fisetin in Cisplatin-Resistant Ovarian Cancer Cells (A2780)
por: Jafarzadeh, Samira, et al.
Publicado: (2021)

A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer
por: Watanabe, Y, et al.
Publicado: (2001)

lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer
por: Li, Qing, et al.
Publicado: (2018)

Deregulation of Exo70 Facilitates Innate and Acquired Cisplatin Resistance in Epithelial Ovarian Cancer by Promoting Cisplatin Efflux
por: Zhao, Yujie, et al.
Publicado: (2021)

MicroRNA-4290 suppresses PDK1-mediated glycolysis to enhance the sensitivity of gastric cancer cell to cisplatin
por: Qian, Yan, et al.
Publicado: (2020)

Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells
por: Huang, Wei, et al.
Publicado: (2016)

Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
por: Chen, Helen H. W., et al.
Publicado: (2010)

The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer
por: O'Byrne, Kenneth J., et al.
Publicado: (2011)

Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer
por: Reyes-González, Jeyshka M., et al.
Publicado: (2020)

Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
por: Schweer, David, et al.
Publicado: (2021)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer
por: Glennon, Kate, et al.
Publicado: (2021)

Ubenimex suppresses glycolysis mediated by CD13/Hedgehog signaling to enhance the effect of cisplatin in liver cancer
por: Shi, Yunyan, et al.
Publicado: (2023)

Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival
por: Dai, Chun-Hua, et al.
Publicado: (2016)

Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway
por: Sun, Ye, et al.
Publicado: (2020)

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer
por: XIE, YA, et al.
Publicado: (2014)

Multi-drug-resistance efflux in cisplatin-naive and cisplatin-exposed A2780 ovarian cancer cells responds differently to cell culture dimensionality
por: Koshkin, Vasilij, et al.
Publicado: (2021)

CDKN3 Overcomes Bladder Cancer Cisplatin Resistance via LDHA-Dependent Glycolysis Reprogramming
por: Li, Mengxuan, et al.
Publicado: (2022)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells
por: BAO, LINGJIE, et al.
Publicado: (2015)

MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
por: Moghbeli, Meysam
Publicado: (2021)

Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells
por: Xu, Lei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_09cvp1nusf7tis50b0er4vedop